How should the latest evidence from BIOADAPTOR and INFINITY-SWEDEHEART RCTs impact our practice?

In this discussion, Davide Capodanno, Stefan Verheye and David Erlinge review the latest evidence from the BIOADAPTOR and INFINITY-SWEDEHEART trials, highlighting the potential of bioadaptive scaffold technology as a new alternative to conventional drug-eluting stents. Long-term data show significant reductions in target lesion failure and cardiovascular death, with benefits emerging over time as the device restores vessel pulsatility and vasomotion. These findings are supported by real-world registry data, suggesting consistent safety and effectiveness across complex patient populations. The key message: bioadaptor technology may represent a promising next step in PCI, encouraging clinicians to consider new platforms that go beyond permanent metallic implants.

This interview was filmed at EuroPCR 2026: see more videos here.